Scholarlink

<p>COVID-19 vaccines were updated to address immune escape from variants of concern (VOC). We explored the impact of ancestral/BA.1 bivalent mRNA booster vaccination (Autumn 2022) on peripheral and nasal antibody and T-cell responses to SARS-CoV-2 in an observational cohort of 133 healthcare workers, building on previous longitudinal vaccination studies. We demonstrate that maintenance of antibody and T-cell responses up to eighteen months following the third vaccine is at least partially driven by intercurrent infection. Boosting with the bivalent vaccine increases the breadth of circulating and nasal antibodies to spike, which waned over time but was still detectable six months post-dose. T-cell responses are well maintained and highly cross-reactive to VOCs irrespective of booster vaccination. Vaccination strongly boosted nasal IgG, but this was short-lived compared to circulating antibodies. Overall, ongoing COVID-19 vaccination provides benefit, boosting immunity in individuals who have not been recently infected, but new strategies may be needed to provide longer-term nasal immunity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dynamic impact of bivalent COVID-19 vaccine boosters on systemic and mucosal antibody and T cell immunity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月27日

查看全文
  • Barbara Kronsteiner,
  • Melissa Govender,
  • Chang Liu,
  • Aiste Dijokaite-Guraliuc,
  • Mohammad Ali,
  • Jennifer Hill,
  • Martha Zewdie,
  • Andrew Cross,
  • James Austin,
  • Amyleigh Watts,
  • Adrienn Angyal,
  • Hailey Hornsby,
  • Priyanka Abraham,
  • Sandra Adele,
  • Srija Moulik,
  • Jodie Harte,
  • Alexander Hargreaves,
  • Yasmin Jiwa,
  • Muneeswaran Selvaraj,
  • Lizzie Stafford,
  • Anni Jamsen,
  • Susan L. Dobson,
  • Sofia Sampaio,
  • Callum Halstead,
  • Amy Steel,
  • Stephanie Longet,
  • Sian E. Faustini,
  • Shona C. Moore,
  • Juthathip Mongkolsapaya,
  • Daniel G. Wootton,
  • James E. D. Thaventhiran,
  • Susan Hopkins,
  • Victoria Hall,
  • Katie Jeffery,
  • Eleanor Barnes,
  • Christopher J. A. Duncan,
  • Rebecca P. Payne,
  • Alex G. Richter,
  • Thushan I. de Silva,
  • Lance Turtle,
  • Gavin R. Screaton,
  • Paul Klenerman,
  • Miles Carroll,
  • Susanna J. Dunachie

摘要

COVID-19 vaccines were updated to address immune escape from variants of concern (VOC). We explored the impact of ancestral/BA.1 bivalent mRNA booster vaccination (Autumn 2022) on peripheral and nasal antibody and T-cell responses to SARS-CoV-2 in an observational cohort of 133 healthcare workers, building on previous longitudinal vaccination studies. We demonstrate that maintenance of antibody and T-cell responses up to eighteen months following the third vaccine is at least partially driven by intercurrent infection. Boosting with the bivalent vaccine increases the breadth of circulating and nasal antibodies to spike, which waned over time but was still detectable six months post-dose. T-cell responses are well maintained and highly cross-reactive to VOCs irrespective of booster vaccination. Vaccination strongly boosted nasal IgG, but this was short-lived compared to circulating antibodies. Overall, ongoing COVID-19 vaccination provides benefit, boosting immunity in individuals who have not been recently infected, but new strategies may be needed to provide longer-term nasal immunity.